CLVS - クロビス・オンコロジ― (Clovis Oncology Inc.)

CLVSのニュース

   Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review  2020/01/16 14:09:00 Zacks Investment Research
Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.
   FDA Grants Priority Review Designation For Clovis Oncology's Rubraca Label Expansion  2020/01/15 15:22:56 Benzinga Feeds
Clovis Oncology Inc (NASDAQ: CLVS ) shares are advancing strongly after the company clinched a regulatory milestone with respect to its oncology drug Rubraca. The Boulder, Colorado-based biopharma company that focuses on the development of anti-cancer agents said the FDA has accepted its sNDA for rucaparib as a monotherapy for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer. Clovis had submitted the regulatory application in November. See Also: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, … Full story available on Benzinga.com
   Clovis Oncology's stock soars after FDA accepts sNDA for prostate cancer treatment  2020/01/15 14:27:00 MarketWatch
Shares of Clovis Oncology Inc. soared 22% in very active premarket trading Wednesday, after the biopharmaceutical company said the supplemental new drug…
   Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium  2019/12/16 13:30:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Professor Dr. Richard P. Baum reported his initial independent clinical experience with FAP-2286 in named-patient use at the International Centers for Precision Oncology (ICPO) Foundation Symposium in Bad Berka, Germany. At Prof. Dr. Baum’s clinic, FAP-2286 was linked to Gallium-68 as a tumor-imaging compound using PET/CT and to Lutetium-177 as a therapeutic agent. In the first named-patient experience wi
   IBI Blogs On Clovis, Intra-Cellular, And Amarin: Your S Secret To Big Profits! - BioSci Capital Partners  2019/12/10 03:20:59 Seeking Alpha
After today's rally, IBI members banked a total of 198.3% returns in Clovis Oncology (CLVS). They also enjoyed the 39.7% on Amarin Corporation (AMRN)'s ADCOM play.
   Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium  2019/12/16 13:30:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Professor Dr. Richard P. Baum reported his initial independent clinical experience with FAP-2286 in named-patient use at the International Centers for Precision Oncology (ICPO) Foundation Symposium in Bad Berka, Germany. At Prof. Dr. Baum’s clinic, FAP-2286 was linked to Gallium-68 as a tumor-imaging compound using PET/CT and to Lutetium-177 as a therapeutic agent. In the first named-patient experience wi
   IBI Blogs On Clovis, Intra-Cellular, And Amarin: Your S Secret To Big Profits! - BioSci Capital Partners  2019/12/10 03:20:59 Seeking Alpha
After today's rally, IBI members banked a total of 198.3% returns in Clovis Oncology (CLVS). They also enjoyed the 39.7% on Amarin Corporation (AMRN)'s ADCOM play.
   Clovis (CLVS) Up 122.5% Since Last Earnings Report: Can It Continue?  2019/12/07 16:31:11 Zacks Investment Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   IBI Blog On Clovis, Amarin, Myovant: Know Your M Secret To Big Profits! - BioSci Capital Partners  2019/11/28 08:22:55 Seeking Alpha
By predicting upcoming rallies, IBI members have banked 254.6% of profits in Clovis Oncology (CLVS). The amazing thing is that they did that in just 24-days!
   Clovis (CLVS) Upgraded to Buy: Here's Why  2019/11/26 14:00:07 Zacks Investment Research
Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium  2019/12/16 13:30:00 Business Wire
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Professor Dr. Richard P. Baum reported his initial independent clinical experience with FAP-2286 in named-patient use at the International Centers for Precision Oncology (ICPO) Foundation Symposium in Bad Berka, Germany. At Prof. Dr. Baum’s clinic, FAP-2286 was linked to Gallium-68 as a tumor-imaging compound using PET/CT and to Lutetium-177 as a therapeutic agent. In the first named-patient experience wi
   IBI Blogs On Clovis, Intra-Cellular, And Amarin: Your S Secret To Big Profits! - BioSci Capital Partners  2019/12/10 03:20:59 Seeking Alpha
After today's rally, IBI members banked a total of 198.3% returns in Clovis Oncology (CLVS). They also enjoyed the 39.7% on Amarin Corporation (AMRN)'s ADCOM play.
   Clovis (CLVS) Up 122.5% Since Last Earnings Report: Can It Continue?  2019/12/07 16:31:11 Zacks Investment Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   IBI Blog On Clovis, Amarin, Myovant: Know Your M Secret To Big Profits! - BioSci Capital Partners  2019/11/28 08:22:55 Seeking Alpha
By predicting upcoming rallies, IBI members have banked 254.6% of profits in Clovis Oncology (CLVS). The amazing thing is that they did that in just 24-days!
   Clovis (CLVS) Upgraded to Buy: Here's Why  2019/11/26 14:00:07 Zacks Investment Research
Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

calendar